Is the HSIL subclassification cytologically real and clinically justified?
- PMID: 20698108
Is the HSIL subclassification cytologically real and clinically justified?
Abstract
The aim of the study was to evaluate the justification of Croatian modification of Bethesda classification after thirteen years of its application, answering the question if the subclassification of high-grade squamous intraepithelial lesion (HSIL) into cervical intraepithelial lesion (CIN) grade 2 (CIN2) and grade 3 (CIN3) is cytologically real and clinically justified. The retrospective study included 3110 women to whom cervical intraepithelial lesion of different grade was diagnosed by cytological examination of vaginal-cervical-endocervical (VCE) smear at Department of Clinical Cytology, Clinical hospital Osijek in period from 1993 to 2005. 57.1% of women were monitored cytologically and colposcopically, while 42.9% of them had also pathohistological examination. The spontaneous regression of cytological finding was noted in 66.3% of the cases. Moderate dysplasia regressed more often (50.98%) than severe dysplasia (31.3%) and more rarely than mild dysplasia (70.1%), which was statistically significant (p < 0.05). Comparing the first and the most serious cytological diagnosis during monitoring, it was found that mild dysplasia was also the most serious diagnosis in 80.1% of the cases, while in 19.9% of patients the initial diagnosis progressed into more severe lesion. Moderate dysplasia was also the most serious cytological diagnosis in 65.35% of the cases, while it progressed in severe dysplasia in 34.1% of the cases. Moderate dysplasia progressed more often into severe dysplasia than mild dysplasia (34.1% vs. 12.7%), which was statistically significant (p < 0.05). Positive predictive value of differential cytological diagnoses mild (23.7%), moderate (40.3%) and severe (90.1%) dysplasia calculated in relation to histological CIN3+ statistically significantly increases for every single diagnosis. Moderate dysplasia and severe dysplasia differ statistically (p > 0.05) in their biological behaviour and histological finding. In fact, 50.9% of moderate dysplasia spontaneously regressed, 14.4% persisted during follow-up, and 59.7% had a histological finding milder than CIN3. Therefore, in almost 65% of moderate dysplasia lesions it is not justified to apply the same diagnostic therapeutic procedures as for severe lesions, which means that cytological subclassification of HSIL into moderate dysplasia and severe dysplasia lesions is clinically justified. Positive predictive value of differential cytological diagnoses mild, moderate and severe dysplasia calculated in relation to histological CIN3+ statistically significantly increases for every single diagnosis, which also confirms that moderate dysplasia can be individual diagnostic category, thus the subclassification of HSIL is cytologically possible.
Similar articles
-
The Bethesda System. A proposal for reporting abnormal cervical smears based on the reproducibility of cytopathologic diagnoses.Arch Pathol Lab Med. 1992 Nov;116(11):1155-8. Arch Pathol Lab Med. 1992. PMID: 1444745
-
Three-Tiered versus Two-Tiered Classification of Squamous Dysplasia in Cervical Cytology: Results of a Follow-Up Study.Acta Cytol. 2019;63(1):44-49. doi: 10.1159/000494984. Epub 2018 Dec 5. Acta Cytol. 2019. PMID: 30517915
-
Interobserver variability in cytologic subclassification of squamous intraepithelial lesions--the Bethesda System vs. World Health Organization classification.Coll Antropol. 2006 Mar;30(1):137-42. Coll Antropol. 2006. PMID: 16617588
-
The Positive Predictive Value of High-Grade Squamous Intraepithelial Lesion on Cytology for the Histological Diagnosis of Cervical Intraepithelial Neoplasia 2 or Higher: A Systematic Review.Acta Cytol. 2019;63(3):206-214. doi: 10.1159/000497110. Epub 2019 Apr 4. Acta Cytol. 2019. PMID: 30947186
-
Glandular lesions of the cervix: diagnostic and therapeutic dilemmas.Baillieres Clin Obstet Gynaecol. 1995 Mar;9(1):105-19. doi: 10.1016/s0950-3552(05)80360-8. Baillieres Clin Obstet Gynaecol. 1995. PMID: 7600721 Review.